Stocks · News reference

Oppenheimer Maintains Outperform on Guardian Pharmacy Service, Raises Price Target to $49

Aug 7, 2026, 2:09 PMBenzinga Newsdesk

Oppenheimer analyst Michael Wiederhorn maintains Guardian Pharmacy Service (NYSE:GRDN) with a Outperform and raises the price target from $43 to $49.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 7, 2026, 2:09 PM
Checked: Aug 7, 2026, 2:09 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 7, 2026, 3:11 PMBenzinga Newsdesk
Guardian Pharmacy Services shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates. Also, Oppenheimer maintained an Outperform rating on the stock and raised its price target from $43 to $49.
Read original at benzinga
GRDN
BenzingaAug 6, 2026, 8:23 PMBenzinga Newsdesk
Guardian Pharmacy Service Q2 Adj. EPS $0.29 Beats $0.27 Estimate, Sales $351.768M Beat $340.045M Estimate
Guardian Pharmacy Service (NYSE:GRDN) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $0.27 by 7.41 percent. This is a 26.09 percent increase over earnings of $0.23 per share
Read original at benzinga
GRDN
BenzingaAug 6, 2026, 8:19 PMBenzinga Newsdesk
Guardian Pharmacy Service Raises FY2026 Sales Guidance from $1.400B-$1.420B to $1.430B-$1.450B vs $1.415B Est
Guardian Pharmacy Service (NYSE:GRDN) raises FY2026 sales outlook from $1.400 billion-$1.420 billion to $1.430 billion-$1.450 billion vs $1.415 billion estimate.
Read original at benzinga
GRDN